Hepatitis B vaccine is currently covered under Medicare Part B for enrollees who are at intermediate or high risk of contracting hepatitis B virus, and, for Part D enrollees who do not fall into those categories the vaccine may be covered under Medicare Part D
However, because Leqembi is subject to the NCD for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease under coverage with evidence development (CED), [241] and because Leqembi was initially marketed and sold under accelerated approval, Leqembi coverage under Part B required the product to be furnished in a randomized controlled trial (RCT) conducted under an investigational new drug (IND) application
We are confirming that only MDPP in-person, distance learning, and in-person with a distance learning component delivery modes, can be used during the extension of the flexibilities allowed under the COVID-19 PHE, as finalized in the CY 2024 PFS final rule (88 FR 79241), not online nor combination with an online component delivery modes
Rebate Reports for applicable calendar quarters in calendar years 2023 and 2024
* * * * * ( (c) * * * (2) * * * (v) Collection of patient specimens for transmittal to a certified laboratory for culturing